Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Actinogen Medical Limited (ATGGF)
OTHER OTC:ATGGF
Holding ATGGF?
Track your performance easily
ATGGF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.01 - $0.02
Previous Close$0.02
Volume32.50K
Average Volume (3M)32.50K
Market Cap
$49.83M
Enterprise Value$39.24M
Total Cash (Recent Filing)AU$16.37M
Total Debt (Recent Filing)AU$165.27K
Price to Earnings (P/E)―
Beta-6.99
Next Earnings
Feb 20, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares OutstandingN/A
10 Day Avg. Volume0
30 Day Avg. Volume32,500
Standard Deviation0.82
R-Squared0.13
Alpha0.16
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)477.34
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Actinogen Medical Limited News
PremiumCompany Announcements
Actinogen Medical’s Promising Advances in Neurological Treatments
PremiumCompany Announcements
Actinogen Medical’s Promising Advances in Neurological Treatments
PremiumCompany Announcements
Actinogen Medical Secures $9 Million R&D Rebate Boost
PremiumCompany Announcements
Actinogen Medical Updates Director’s Securities Holdings
PremiumCompany Announcements
Actinogen Medical Expands Shares Amid Drug Development Progress
PremiumCompany Announcements
Actinogen Medical Expands Market Presence with New SecuritiesPremiumCompany Announcements
Actinogen Medical Advances in Neurological Drug Development
PremiumCompany Announcements
Actinogen Medical Highlights Alzheimer’s Research ProgressOptions Prices
Currently, No data available
---
Ownership Overview
ATGGF FAQ
What was Actinogen Medical Limited’s price range in the past 12 months?
Actinogen Medical Limited lowest stock price was $0.01 and its highest was $0.01 in the past 12 months.
What is Actinogen Medical Limited’s market cap?
Currently, no data Available
When is Actinogen Medical Limited’s upcoming earnings report date?
Actinogen Medical Limited’s upcoming earnings report date is Feb 20, 2025 which is in 86 days.
How were Actinogen Medical Limited’s earnings last quarter?
Actinogen Medical Limited released its earnings results on Aug 30, 2024. The company reported >-$0.001 earnings per share for the quarter, missing the consensus estimate of N/A by >-$0.001.
Is Actinogen Medical Limited overvalued?
According to Wall Street analysts Actinogen Medical Limited’s price is currently Overvalued.
Does Actinogen Medical Limited pay dividends?
Actinogen Medical Limited does not currently pay dividends.
What is Actinogen Medical Limited’s EPS estimate?
Actinogen Medical Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Actinogen Medical Limited have?
Actinogen Medical Limited has 3,082,668,000 shares outstanding.
What happened to Actinogen Medical Limited’s price movement after its last earnings report?
Actinogen Medical Limited reported an EPS of >-$0.001 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Actinogen Medical Limited?
Currently, no hedge funds are holding shares in ATGGF
---
Actinogen Medical Limited Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
ATGGF Sentiment 91%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $730.7K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.14%
12-Months-Change
Fundamentals
Return on Equity
-77.17%
Trailing 12-Months
Asset Growth
40.59%
Trailing 12-Months
Company Description
Actinogen Medical Limited
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological and metabolic diseases. Geographically, it operates and derives revenue from Australia.
---
Technical Analysis
Bioxcel Therapeutics
―
Cyclerion Therapeutics
―
Corbus Pharmaceuticals
―
ESSA Pharma
―
---